Puma Biotechnology, Inc. has grown revenue 0.16% a year over three years and −1.9% a year over five. Revenue growth, 3-year annual rate: +0.16% (Biotechnology median +17%). Revenue growth, 5-year rate: −1.9%, growth has picked up over the last three years. Years of annual history on file: 17, FY2008 to FY2025, as filed.

PBYIPuma Biotechnology, Inc.

Healthcare

$9.98+93% 1Y

$9.98

$4.7352 weeks$9.98

Latest close: a new 52-week highOct 8, 2026what changed →

Is it growing?

Watch

Growth is fading: revenue shrinking (−3% year on year), earnings down −47% year on year, and operating margin narrowing (−6.6 points).

3 to watch

Revenue trend−3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −2% a year.

Earnings trend−47% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−6.6 points operating

Trailing-twelve-month operating margin, 11.3% now against 17.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is PBYI growing?

Puma Biotechnology, Inc. has grown revenue 0.16% a year over three years and −1.9% a year over five.

+0.16%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −1.9%
Revenue growth, 5-year rate · +0.16% over three · growth has picked up over the last three years
Years of annual history on file: 17
Years of annual history on file · FY2008 to FY2025, as filed

Details›